{"version":"1.0","provider_name":"Merck.com","provider_url":"https:\/\/vip2-msd.com\/merckcom-migrated","author_name":"Merck.com","author_url":"https:\/\/vip2-msd.com\/merckcom-migrated","title":"Merck Completes Acquisition of Verona Pharma - Merck.com","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"6qLbh6rajq\"><a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-verona-pharma\/\">Merck Completes Acquisition of Verona Pharma<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-verona-pharma\/embed\/#?secret=6qLbh6rajq\" width=\"600\" height=\"338\" title=\"&#8220;Merck Completes Acquisition of Verona Pharma&#8221; &#8212; Merck.com\" data-secret=\"6qLbh6rajq\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/vip2-msd.com\/merckcom-migrated\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Acquisition strengthens Merck\u2019s cardio-pulmonary portfolio with addition of Ohtuvayre\u00ae (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market. \u201cThe Verona Pharma acquisition strengthens and complements our portfolio of treatments for patients with cardio-pulmonary diseases to include Ohtuvayre, while delivering near and long-term growth as well as value for shareholders,\u201d said Robert M. Davis, chairman and chief executive officer, Merck. \u201cThe addition of Ohtuvayre is another strong example of our business development strategy, which focuses on opportunities where compelling science and","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007814715r1&amp;sid=q4-prod&amp;distro=nx&amp;lang=en"}